Researchers Propose Adding a Molecular Classifier to TNM Staging in Non-Small Cell Lung Cancer
Experts acknowledged the growing importance of genomics to the field, but said more research is needed to justify changing current practices.
Non-Small Cell Lung Cancer
Entrectinib Treatment May Eventually Be an Option for ROS1 Fusion-Positive NSCLC
Disease control with entrectinib was found to be active and durable in ROS1 fusion-positive NSCLC.
Study Supports Standard-Dose RT in Chemoradiotherapy for Patients With Stage III Unresectable NSCLC
Long-term follow-up of the Radiation Therapy Oncology Group 0617 trial continues to support a 60-Gy radiation therapy dose as the standard of care.
Osimertinib Extended OS in EGFR-Mutated Advanced NSCLC
The third-generation drug performed better than erlotinib or gefitinib, according to researchers.
Alectinib Found Active in Advanced ALK-Positive Advanced NSCLC Characterized by Crizotinib Resistance Mutations
In this analysis, data from a pair of phase 2 studies of patients with ALK-positive, crizotinib-resistant advanced NSCLC were pooled.
Overall Survival Benefit With Durvalumab Continues at 3-Year Follow-Up
Patients with advanced non-small cell lung cancer who did not have disease progression after chemoradiotherapy appeared to have a long-term survival benefit with durvalumab.
Characteristics Identified for Checkpoint Inhibitor-Resistant Patients
Patients with NSCLC who did not respond to immune checkpoint blockade had unique molecular characteristics, revealing possible therapeutic targets.
No PRO Detriments Observed With Durvalumab for Stage III Unresectable NSCLC Compared With Placebo
No significant differences in PROs were observed among patients treated with subsequent durvalumab after chemoradiation therapy for stage III unresectable NSCLC compared with those who received subsequent placebo.
Ceritinib Plus Nivolumab in NSCLC Characterized by an ALK Mutation
Among patients who were naive to ALK inhibition, the overall response rate was 83% for the 450-mg dose and 60% for the 300-mg dose.
Genomic Assay Shows Utility in Selecting NSCLC Patients for Targeted Therapy
Next-generation sequencing of circulating tumor DNA (ctDNA) may identify patients who are likely to benefit from targeted therapy for NSCLC.
Next post in IASLC North America 2019
